亚洲/中国三代 EGFR TKI：伏美替尼、阿美替尼、Lazertinib 作为背景选项
类型: III期临床试验 / 地区可及性背景 发表日期: 2023-06-28 入库日期: 2026-05-21 来源: PubMed / Lancet Respiratory Medicine / JCO 标签: EGFR L858R, 伏美替尼, 阿美替尼, Lazertinib, CNS, 中国可及性, 三代TKI
Citations
Shi Y, et al. Furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive NSCLC (FURLONG). Lancet Respiratory Medicine. 2022. PMID: 35662408. DOI: 10.1016/S2213-2600(22)00168-0
Cho BC, et al. Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced NSCLC: LASER301. Journal of Clinical Oncology. 2023. PMID: 37379502. DOI: 10.1200/JCO.23.00515
PubMed search for aumolertinib/AENEAS: aumolertinib AENEAS EGFR-mutated NSCLC
Why it matters for mom
Mom is already on osimertinib, so these are not automatic substitutes. They matter because China/Asia treatment availability can differ from US/EU pathways, and later decisions may include questions about switching EGFR TKIs, CNS coverage, access, and toxicity.
Practical takeaways
- These drugs are best viewed as context, not a proven post-osimertinib rescue strategy by themselves.
- If doctors discuss switching among third-generation EGFR TKIs, ask what resistance mechanism or toxicity reason supports the switch.
- For CNS risk, third-generation CNS penetration remains a key consideration even when brain MRI is currently negative.
Questions for doctors
- Is there any molecular reason to switch from osimertinib to another third-generation EGFR TKI?
- Would a switch preserve CNS protection?
- Are local Chinese approvals/trials relevant if standard post-osimertinib options are limited?